Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease.

View / Open Files

Published version (PDF, 1Mb)

Authors

Roberts, Kevin J

Cubitt, Marion F

Carlton, Timothy M

Rodrigues-Duarte, Lurdes

Maggiore, Luana

Chai, Ray

Clare, Simon

Harcourt, Katherine

MacDonald, Thomas T

Ray, Keith P

Vossenkämper, Anna

West, Michael R

Crowe, J Scott

Show moreShow less

Publication Date

2021-09-30

Journal Title

Scientific reports

ISSN

2045-2322

Volume

11

Issue

1

Pages

19422

Language

eng

Type

Article

This Version

VoR

Physical Medium

Electronic

Metadata

Show full item record

Citation

Roberts, K. J., Cubitt, M. F., Carlton, T. M., Rodrigues-Duarte, L., Maggiore, L., Chai, R., Clare, S., et al. (2021). Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease.. Scientific reports, 11 (1), 19422. https://doi.org/10.1038/s41598-021-97236-0

Identifiers

External DOI: https://doi.org/10.1038/s41598-021-97236-0

This record's URL: https://www.repository.cam.ac.uk/handle/1810/330154





Rights

Attribution 4.0 International

Licence URL: https://creativecommons.org/licenses/by/4.0/